A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...

Innovation is never easy. It requires the audacity to create a new path, one where we will encounter novel obstacles that demand both resourcefulness and bold imagination. But when we stand together, ...

Global Talent Acquisition Pioneer Endorses Revolutionary Talent Intelligence Platform That Reduces Search Time From Days to ...

Human egg cells are often prone to chromosomal errors. As women age, the error rate increases sharply - and can contribute to infertility, pregnancy ...

Human egg cells are often prone to chromosomal errors. As women age, the error rate increases sharply—and can contribute to ...

John L. Hennessy is President Emeritus of Stanford University as well as the James F. and Mary Lynn Gibbons Professor of ...

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

Gene editing techniques, including CRISPR, prime editing, and nucleases, allow scientists to tackle genetic diseases, cancer, ...

According to SNS Insider, the global Cell Line Development Market was valued at USD 5.46 billion in 2023 and is projected to reach USD 12.56 billion by 2032, expanding at a CAGR of 9.66% from ...

The global sales of DNA polymerase are estimated to be worth USD 397.7 million in 2025 and anticipated to reach a value of ...